{"id": "HPRD50.d0.s0_HPRD50.d0.s0.p0", "text": "Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "text_with_entity_marker": "Cloning and characterization of two evolutionarily conserved subunits ([E1]TFIIIC102[/E1] and [E2]TFIIIC63[/E2]) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIIC102", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "pm0125479", "entity_1_type_id": 0, "entity_2": "TFIIIC63", "entity_2_idx": [[85, 93]], "entity_2_idx_in_text_with_entity_marker": [98, 106], "entity_2_type": "pm0100174", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "HPRD50.d3.s2_HPRD50.d3.s2.p1", "text": "IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor", "text_with_entity_marker": "[E1]IL-6[/E1] promotes coprecipitation of p85 with gp130, the signal-transducing component of the [E2]IL-6 receptor[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0110911", "entity_1_type_id": 11, "entity_2": "IL-6 receptor", "entity_2_idx": [[89, 102]], "entity_2_idx_in_text_with_entity_marker": [102, 115], "entity_2_type": "pm0106299", "entity_2_type_id": 15}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s0_HPRD50.d4.s0.p0", "text": "In solution, FGFR4ed formed complexes with acidic FGF (FGF-1) and basic FGF (FGF-2), both in the presence and absence of heparin", "text_with_entity_marker": "In solution, FGFR4ed formed complexes with [E1]acidic FGF (FGF-1)[/E1] and [E2]basic FGF (FGF-2)[/E2], both in the presence and absence of heparin", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "acidic FGF (FGF-1)", "entity_1_idx": [[43, 61]], "entity_1_idx_in_text_with_entity_marker": [47, 65], "entity_1_type": "pm0124654", "entity_1_type_id": 16, "entity_2": "basic FGF (FGF-2)", "entity_2_idx": [[66, 83]], "entity_2_idx_in_text_with_entity_marker": [79, 96], "entity_2_type": "pm0106166", "entity_2_type_id": 17}], "directed": false, "reverse": false}
{"id": "HPRD50.d5.s4_HPRD50.d5.s4.p0", "text": "In contrast, LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a cytohesin-1 mutant, which fails to catalyze ARF GDP-GTP exchange in vitro", "text_with_entity_marker": "In contrast, LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a [E1]cytohesin-1[/E1] mutant, which fails to catalyze [E2]ARF[/E2] GDP-GTP exchange in vitro", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cytohesin-1", "entity_1_idx": [[125, 136]], "entity_1_idx_in_text_with_entity_marker": [129, 140], "entity_1_type": "pm0124251", "entity_1_type_id": 20, "entity_2": "ARF", "entity_2_idx": [[169, 172]], "entity_2_idx_in_text_with_entity_marker": [182, 185], "entity_2_type": "pm0126206", "entity_2_type_id": 22}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s0_HPRD50.d6.s0.p0", "text": "Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of Jak2, p125FAK, and paxillin", "text_with_entity_marker": "Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of [E1]Jak2[/E1], p125FAK, and [E2]paxillin[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak2", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "paxillin", "entity_2_idx": [[121, 129]], "entity_2_idx_in_text_with_entity_marker": [134, 142], "entity_2_type": "pm0119378", "entity_2_type_id": 24}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s3_HPRD50.d6.s3.p0", "text": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and Jak2, STAT3, p125FAK, and paxillin phosphorylation", "text_with_entity_marker": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and [E1]Jak2[/E1], [E2]STAT3[/E2], p125FAK, and paxillin phosphorylation", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak2", "entity_1_idx": [[98, 102]], "entity_1_idx_in_text_with_entity_marker": [102, 106], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "STAT3", "entity_2_idx": [[104, 109]], "entity_2_idx_in_text_with_entity_marker": [117, 122], "entity_2_type": "pm0118656", "entity_2_type_id": 25}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s3_HPRD50.d6.s3.p2", "text": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and Jak2, STAT3, p125FAK, and paxillin phosphorylation", "text_with_entity_marker": "Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and Jak2, [E1]STAT3[/E1], p125FAK, and [E2]paxillin[/E2] phosphorylation", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "STAT3", "entity_1_idx": [[104, 109]], "entity_1_idx_in_text_with_entity_marker": [108, 113], "entity_1_type": "pm0118656", "entity_1_type_id": 25, "entity_2": "paxillin", "entity_2_idx": [[124, 132]], "entity_2_idx_in_text_with_entity_marker": [137, 145], "entity_2_type": "pm0119378", "entity_2_type_id": 24}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s4_HPRD50.d10.s4.p1", "text": "These results identify CD43 as a T cell counterreceptor for sialoadhesin and suggest that in addition to its anti-adhesive role CD43 may promote cell-cell interactions", "text_with_entity_marker": "These results identify [E1]CD43[/E1] as a T cell counterreceptor for sialoadhesin and suggest that in addition to its anti-adhesive role [E2]CD43[/E2] may promote cell-cell interactions", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD43", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "CD43", "entity_2_idx": [[128, 132]], "entity_2_idx_in_text_with_entity_marker": [141, 145], "entity_2_type": "pm0122945", "entity_2_type_id": 36}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p5", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that [E1]CLIP-170[/E1] and [E2]LIS1[/E2] regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CLIP-170", "entity_1_idx": [[158, 166]], "entity_1_idx_in_text_with_entity_marker": [162, 170], "entity_1_type": "pm0124985", "entity_1_type_id": 43, "entity_2": "LIS1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "pm0110467", "entity_2_type_id": 44}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s0_HPRD50.d15.s0.p0", "text": "Physical association of beta 2 integrin with GPI-80, a novel glycosylphosphatidylinositol-anchored protein with potential for regulating adhesion and migration", "text_with_entity_marker": "Physical association of [E1]beta 2 integrin[/E1] with [E2]GPI-80[/E2], a novel glycosylphosphatidylinositol-anchored protein with potential for regulating adhesion and migration", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "beta 2 integrin", "entity_1_idx": [[24, 39]], "entity_1_idx_in_text_with_entity_marker": [28, 43], "entity_1_type": "pm0114514", "entity_1_type_id": 48, "entity_2": "GPI-80", "entity_2_idx": [[45, 51]], "entity_2_idx_in_text_with_entity_marker": [58, 64], "entity_2_type": "pm0100260", "entity_2_type_id": 49}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p12", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a (Gadd45), Gadd45b ([E1]MyD118[/E1]), and [E2]Gadd45g[/E2] (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyD118", "entity_1_idx": [[27, 33]], "entity_1_idx_in_text_with_entity_marker": [31, 37], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45g", "entity_2_idx": [[40, 47]], "entity_2_idx_in_text_with_entity_marker": [53, 60], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s3_HPRD50.d16.s3.p0", "text": "Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "text_with_entity_marker": "Yet, whether [E1]Gadd45b[/E1] and/or [E2]Gadd45g[/E2] function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[13, 20]], "entity_1_idx_in_text_with_entity_marker": [17, 24], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45g", "entity_2_idx": [[28, 35]], "entity_2_idx_in_text_with_entity_marker": [41, 48], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p2", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that [E1]Gadd45b[/E1] and Gadd45g, as well as GADD45a, interact with both [E2]Cdk1[/E2] and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45b", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Cdk1", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p3", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that [E1]Gadd45b[/E1] and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the [E2]Cdk1[/E2]/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45b", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Cdk1", "entity_2_idx": [[166, 170]], "entity_2_idx_in_text_with_entity_marker": [179, 183], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p0", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of [E1]Cdk1[/E1]/cyclinB1 kinase activity by [E2]Gadd45b[/E2] and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdk1", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "pm0113152", "entity_1_type_id": 53, "entity_2": "Gadd45b", "entity_2_idx": [[47, 54]], "entity_2_idx_in_text_with_entity_marker": [60, 67], "entity_2_type": "pm0114403", "entity_2_type_id": 51}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s3_HPRD50.d18.s3.p0", "text": "The interaction with p120(ctn) is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and E-cadherin expression", "text_with_entity_marker": "The interaction with [E1]p120(ctn)[/E1] is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and [E2]E-cadherin[/E2] expression", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p120(ctn)", "entity_1_idx": [[21, 30]], "entity_1_idx_in_text_with_entity_marker": [25, 34], "entity_1_type": "pm0101886", "entity_1_type_id": 60, "entity_2": "E-cadherin", "entity_2_idx": [[137, 147]], "entity_2_idx_in_text_with_entity_marker": [150, 160], "entity_2_type": "pm0115783", "entity_2_type_id": 62}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s4_HPRD50.d18.s4.p1", "text": "Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific", "text_with_entity_marker": "Catalytic domains of the tyrosine phosphatases [E1]PTP-PEST[/E1], CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of [E2]DEP1[/E2] with these proteins is specific", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTP-PEST", "entity_1_idx": [[47, 55]], "entity_1_idx_in_text_with_entity_marker": [51, 59], "entity_1_type": "pm0117107", "entity_1_type_id": 63, "entity_2": "DEP1", "entity_2_idx": [[185, 189]], "entity_2_idx_in_text_with_entity_marker": [198, 202], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s0_HPRD50.d19.s0.p0", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "text_with_entity_marker": "[E1]p300[/E1]/[E2]cAMP-response-element-binding-protein[/E2] ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "cAMP-response-element-binding-protein", "entity_2_idx": [[5, 42]], "entity_2_idx_in_text_with_entity_marker": [18, 55], "entity_2_type": "pm0100874", "entity_2_type_id": 66}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s1_HPRD50.d19.s1.p1", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "text_with_entity_marker": "[E1]p300[/E1]/cAMP-response-element-binding-protein ('[E2]CREB[/E2]')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "CREB", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "pm0100874", "entity_2_type_id": 66}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s1_HPRD50.d20.s1.p0", "text": "We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins Imp3 and Imp4", "text_with_entity_marker": "We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins [E1]Imp3[/E1] and [E2]Imp4[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Imp3", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "Imp4", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "pm0104160||pm0117832", "entity_2_type_id": 69}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s3_HPRD50.d20.s3.p0", "text": "The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "text_with_entity_marker": "The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human [E1]Imp3[/E1] and [E2]Imp4[/E2] proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Imp3", "entity_1_idx": [[104, 108]], "entity_1_idx_in_text_with_entity_marker": [108, 112], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "Imp4", "entity_2_idx": [[113, 117]], "entity_2_idx_in_text_with_entity_marker": [126, 130], "entity_2_type": "pm0104160||pm0117832", "entity_2_type_id": 69}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s1_HPRD50.d21.s1.p1", "text": "In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R", "text_with_entity_marker": "In contrast to [E1]OX1R[/E1], the potency of direct activation of CB1 was not affected by co-expression with [E2]OX1R[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "OX1R", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "pm0111533", "entity_1_type_id": 72, "entity_2": "OX1R", "entity_2_idx": [[100, 104]], "entity_2_idx_in_text_with_entity_marker": [113, 117], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p2", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "[E1]Gab1[/E1] and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, [E2]Shp-2[/E2], phosphatidylinositol 3-kinase, Shc, and Crk", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "Shp-2", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "pm0122382", "entity_2_type_id": 78}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p6", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "Gab1 and [E1]Gab2[/E1] are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, [E2]phosphatidylinositol 3-kinase[/E2], Shc, and Crk", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab2", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "pm0111574", "entity_1_type_id": 76, "entity_2": "phosphatidylinositol 3-kinase", "entity_2_idx": [[166, 195]], "entity_2_idx_in_text_with_entity_marker": [179, 208], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p9", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, [E1]Shp-2[/E1], [E2]phosphatidylinositol 3-kinase[/E2], Shc, and Crk", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Shp-2", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "pm0122382", "entity_1_type_id": 78, "entity_2": "phosphatidylinositol 3-kinase", "entity_2_idx": [[166, 195]], "entity_2_idx_in_text_with_entity_marker": [179, 208], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p7", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and [E1]NudC[/E1], show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that [E2]NudC[/E2] is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s0_HPRD50.d24.s0.p0", "text": "Specific interaction of Egr1 and c/EBPbeta leads to the transcriptional activation of the human low density lipoprotein receptor gene", "text_with_entity_marker": "Specific interaction of [E1]Egr1[/E1] and c/EBPbeta leads to the transcriptional activation of the human [E2]low density lipoprotein receptor[/E2] gene", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Egr1", "entity_1_idx": [[24, 28]], "entity_1_idx_in_text_with_entity_marker": [28, 32], "entity_1_type": "pm0115655", "entity_1_type_id": 87, "entity_2": "low density lipoprotein receptor", "entity_2_idx": [[96, 128]], "entity_2_idx_in_text_with_entity_marker": [109, 141], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p3", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the LDL receptor ([E1]LDLR[/E1]) promoter mediates [E2]oncostatin M[/E2] (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LDLR", "entity_1_idx": [[70, 74]], "entity_1_idx_in_text_with_entity_marker": [74, 78], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "oncostatin M", "entity_2_idx": [[94, 106]], "entity_2_idx_in_text_with_entity_marker": [107, 119], "entity_2_type": "pm0100359", "entity_2_type_id": 89}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s1_HPRD50.d25.s1.p0", "text": "BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "text_with_entity_marker": "BACKGROUND: Both [E1]androgen receptor[/E1] (AR) and orphan receptor [E2]TR2[/E2] (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "androgen receptor", "entity_1_idx": [[17, 34]], "entity_1_idx_in_text_with_entity_marker": [21, 38], "entity_1_type": "pm0125088", "entity_1_type_id": 91, "entity_2": "TR2", "entity_2_idx": [[60, 63]], "entity_2_idx_in_text_with_entity_marker": [73, 76], "entity_2_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_2_type_id": 90}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p4", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "TBP-1 associates with the beta-domain of [E1]pVHL[/E1] and complexes with pVHL and [E2]Hif1 alpha[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[41, 45]], "entity_1_idx_in_text_with_entity_marker": [45, 49], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[74, 84]], "entity_2_idx_in_text_with_entity_marker": [87, 97], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s6_HPRD50.d26.s6.p4", "text": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha", "text_with_entity_marker": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with [E1]Hif1 alpha[/E1], but not TBP-1, and does not promote degradation of [E2]Hif1 alpha[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hif1 alpha", "entity_1_idx": [[72, 82]], "entity_1_idx_in_text_with_entity_marker": [76, 86], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "Hif1 alpha", "entity_2_idx": [[135, 145]], "entity_2_idx_in_text_with_entity_marker": [148, 158], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p0", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of [E1]pVHL[/E1] to degrade [E2]Hif1 alpha[/E2] depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[37, 47]], "entity_2_idx_in_text_with_entity_marker": [50, 60], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s0_HPRD50.d27.s0.p2", "text": "Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "text_with_entity_marker": "[E1]Pinin[/E1]/DRS/memA interacts with SRp75, [E2]SRm300[/E2] and SRrp130 in corneal epithelial cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Pinin", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0118763", "entity_1_type_id": 96, "entity_2": "SRm300", "entity_2_idx": [[37, 43]], "entity_2_idx_in_text_with_entity_marker": [50, 56], "entity_2_type": "pm0117461", "entity_2_type_id": 98}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s2_HPRD50.d28.s2.p2", "text": "In contrast, phosphorylation of SMC1 by ATR is independent of Rad17 and replication protein A, suggesting that the signaling pathway leading to SMC1 phosphorylation is distinct from that mediated by the checkpoint proteins", "text_with_entity_marker": "In contrast, phosphorylation of SMC1 by ATR is independent of [E1]Rad17[/E1] and replication protein A, suggesting that the signaling pathway leading to [E2]SMC1[/E2] phosphorylation is distinct from that mediated by the checkpoint proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rad17", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "pm0117336", "entity_1_type_id": 102, "entity_2": "SMC1", "entity_2_idx": [[144, 148]], "entity_2_idx_in_text_with_entity_marker": [157, 161], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d31.s1_HPRD50.d31.s1.p0", "text": "We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes", "text_with_entity_marker": "We show here that [E1]Cdc25[/E1] phosphatase associates with [E2]raf1[/E2] in somatic mammalian cells and in meiotic frog oocytes", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdc25", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "pm0106635||pm0109000", "entity_1_type_id": 113, "entity_2": "raf1", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "pm0117803", "entity_2_type_id": 112}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p1", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans ([E1]perlecan[/E1], biglycan, [E2]decorin[/E2], and versican) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "decorin", "entity_2_idx": [[81, 88]], "entity_2_idx_in_text_with_entity_marker": [94, 101], "entity_2_type": "pm0108608", "entity_2_type_id": 116}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s3_HPRD50.d32.s3.p2", "text": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "text_with_entity_marker": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell ([E1]SMC[/E1])-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with [E2]perlecan[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[130, 133]], "entity_1_idx_in_text_with_entity_marker": [134, 137], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "perlecan", "entity_2_idx": [[290, 298]], "entity_2_idx_in_text_with_entity_marker": [303, 311], "entity_2_type": "pm0116983", "entity_2_type_id": 114}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p19", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and [E1]biglycan[/E1], two dermatan sulfate proteoglycans, and lack of binding by versican/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "biglycan", "entity_1_idx": [[123, 131]], "entity_1_idx_in_text_with_entity_marker": [127, 135], "entity_1_type": "pm0124379", "entity_1_type_id": 115, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s1_HPRD50.d33.s1.p1", "text": "However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53", "text_with_entity_marker": "However, cytokines, in particular [E1]IL-2[/E1] and IL-4, potentiated the DNA synthesis induced by cross-linking of [E2]CD53[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-2", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [38, 42], "entity_1_type": "pm0110478", "entity_1_type_id": 128, "entity_2": "CD53", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "pm0107494", "entity_2_type_id": 125}], "directed": false, "reverse": false}
{"id": "HPRD50.d34.s1_HPRD50.d34.s1.p0", "text": "The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans", "text_with_entity_marker": "The fact that the [E1]apoB[/E1] mRNA editing protein also exists as a [E2]homodimer[/E2] has important implications for the mechanism of apoB mRNA editing in humans", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "apoB", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0126272", "entity_1_type_id": 130, "entity_2": "homodimer", "entity_2_idx": [[61, 70]], "entity_2_idx_in_text_with_entity_marker": [74, 83], "entity_2_type": "pm0125626", "entity_2_type_id": 132}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s4_HPRD50.d36.s4.p2", "text": "Transient expression of CD22 and a null mutant of PTP-1C (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of CD22 and its interaction with PTP-1CM", "text_with_entity_marker": "Transient expression of CD22 and a null mutant of [E1]PTP-1C[/E1] (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of [E2]CD22[/E2] and its interaction with PTP-1CM", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PTP-1C", "entity_1_idx": [[50, 56]], "entity_1_idx_in_text_with_entity_marker": [54, 60], "entity_1_type": "pm0105676", "entity_1_type_id": 136, "entity_2": "CD22", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "pm0119833", "entity_2_type_id": 135}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s1_HPRD50.d38.s1.p0", "text": "Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links", "text_with_entity_marker": "Specific glutamines or lysines of [E1]involucrin[/E1] were used to cross-link the different proteins, such as glutamines 495 and 496 to [E2]desmoplakin[/E2], glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "involucrin", "entity_1_idx": [[34, 44]], "entity_1_idx_in_text_with_entity_marker": [38, 48], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "desmoplakin", "entity_2_idx": [[127, 138]], "entity_2_idx_in_text_with_entity_marker": [140, 151], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p0", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "[E1]Bcl3[/E1] specifically interacted with the general transcription factors [E2]TFIIB[/E2], TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Bcl3", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126712", "entity_1_type_id": 151, "entity_2": "TFIIB", "entity_2_idx": [[68, 73]], "entity_2_idx_in_text_with_entity_marker": [81, 86], "entity_2_type": "pm0112772", "entity_2_type_id": 153}], "directed": false, "reverse": false}
